REGENXBIO Inc. (RGNX)
RGNX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/0001193125-26-094013-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | RGNX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2015 |
| SEC CIK | 0001590877 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DELAWARE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $170.4M |
| Net income | -$193.9M |
| Operating income | -$161.2M |
| Net margin | -113.8% |
| Operating margin | -94.6% |
| Revenue growth | +104.5% |
| Cash | $34.5M |
| Total assets | $453.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern within 12 months from the date these consolidated financial statements were issued." | 10-Q 2026-11-05 |
| Cash and burn | $95.8M cash; operating cash flow -$38.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 66,122,600 (2026-10-30); 50,623,086 a year earlier; 43,991,980 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-07-17 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Washington, District of Columbia, United States | PCAOB Form AP 2026-03-19 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $950K, sold $1.2M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $9.2M | -$40.7M | $38.6M | $95.8M | No debt tags | $153.9M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $108.0M | $22.7M | -$62.2M | $36.5M | No debt tags | $174.5M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $6.4M | -$90.1M | -$76.2M | $15.2M | No debt tags | $87.8M | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $30.3M | -$67.1M | -$52.3M | $34.5M | No debt tags | $170.4M | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | $29.7M | -$61.9M | -$56.0M | $58.8M | No debt tags | $161.3M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $21.4M | -$70.9M | -$49.3M | $79.6M | No debt tags | $155.8M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $89.0M | $6.1M | $33.6M | $130.1M | No debt tags | $156.7M | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $21.2M | -$51.2M | -$31.6M | $57.5M | No debt tags | $83.3M | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-07-17 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-14 |
Source: SEC EDGAR submissions feed, 806 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.3% |
| 1 month | +5.2% |
| 3 months | -28.3% |
| Year to date | -46.9% |
| 1 year | -34.4% |
| From 52-week high | -52.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CADL | Candel Therapeutics Inc. | $5.81 | -6.29% | $455.8M |
| FENC | Fennec Pharmaceuticals Inc. | $12.76 | +9.81% | $450.5M |
| ETRA | Electra Therapeutics Inc. | $8.31 | -6.00% | $522.4M |
| ENTX | Entera Bio Ltd. | $3.02 | -2.89% | $525.9M |
| VALN | Valneva SE | $5.65 | -0.18% | $536.1M |
| DNA | Ginkgo Bioworks Holdings Inc. | $8.50 | -11.55% | $551.0M |
| TVGN | Tevogen Inc. | $6.22 | +3.67% | $422.2M |
| TECX | Tectonic Therapeutic Inc. | $20.98 | -0.76% | $418.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier